Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Files for $115 Million IPO in the US

publication date: Aug 16, 2017
Shanghai's Zai Lab has officially announced its IPO by filing an initial prospectus with the US SEC. According to the prospectus, Zai will seek to stage an IPO on the NASDAQ exchange for as much as $115 million. Details of the offering are not included in the preliminary filing, though the filing specifies some operating details: Zai spent $32.1 million in R&D during 2016 and another $20.9 million during the first six months of 2017. On June 30, 2017, the company had $92.6 million in cash on hand after raising $164.5 million in equity financings over its three-year history. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital